FI4010322T3 - (s)-2-(((s)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yyli)amino)-n-(1-(2-metyyli-1-(neopentyyliamino)propan-2-yyli)-1h-imidatsol-4-yyli)pentaaniamidin kiinteitä olomuotoja ja niiden käyttö - Google Patents
(s)-2-(((s)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yyli)amino)-n-(1-(2-metyyli-1-(neopentyyliamino)propan-2-yyli)-1h-imidatsol-4-yyli)pentaaniamidin kiinteitä olomuotoja ja niiden käyttöInfo
- Publication number
- FI4010322T3 FI4010322T3 FIEP19758589.6T FI19758589T FI4010322T3 FI 4010322 T3 FI4010322 T3 FI 4010322T3 FI 19758589 T FI19758589 T FI 19758589T FI 4010322 T3 FI4010322 T3 FI 4010322T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- crystalline form
- particle size
- neopentylamino
- pentanamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. (S)-2-(((S)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yylijamino)-N-(1-(2- metyyli-1-(neopentyyliamino)propan-2-yyli)-1H-imidatsol-4-yyli)pentaaniamidin hydrobromidisuolan kiteinen muoto, jolla on kaava (I) F O NN VW otan i H HBr F > HBr (D, jossa kiteinen muoto on kiteinen muoto A, jolloin muoto A on tunnettu XRPD-kuviosta, jonka piikit ovat 8,8 + 0,2, 9,8 + 0,2 ja 23,3 + 0,2 kaksi theeta -asteen asemissa.
2. Patenttivaatimuksen 1 mukainen kiteinen muoto, jolloin muoto A on lisäksi tunnettu (a) — vedettömyydestä (b) noin 254 *C:n sulamispisteestä (c) —XRPD-kuviosta, jonka piikit ovat 8,8 + 0,2, 9,8 + 0,2, 23,3 + 0,2, 25,4 + 0,2, 28,0 +02ja 29,3 + 0,2 kaksi theeta -asteen asemissa, edullisesti 8,8 + 0,2, 9,8 + 0,2, 20,0 + 0,2, 23,3 + 0,2, 25,4 + 0,2, 28,0 + 0,2, 29,3 + 0,2 ja 32,5 + 0,2 kaksi theeta -asteen asemissa (d) olennaisesti kuviossa 1 esitetyn kaltaisesta XRPD-kuviosta (e) = TGA-profiilista, joka on olennaisesti kuvan 2 mukainen —(f) DSC-profiilista, joka on olennaisesti kuvan 3 mukainen (9) alkeiskopista, joka indeksoituu primitiiviseksi monokliiniseksi (h) alkeiskopista, jonka a-arvo on noin 10,035 A, b-arvo noin 7,532 A ja c-arvo noin 20,092 A; jaltai (i) alkeiskopista, jonka tilavuus on noin 1 518,1 AS.
3. Patenttivaatimuksen 1 tai 2 mukainen kiteinen muoto, jolloin muodolla A (a) ei ole olennaisesti lainkaan muita polymorfisia muotoja tai jolloin kiteisen muodon polymorfinen puhtaus on vähintään 90 %, edullisesti vähintään 99 %; ja/tai
EP4010322 2 (b) on yksi tai useampi D[V,0,1]-hiukkaskoko, joka on noin 0,5—15 um, D[V,0,50]- hiukkaskoko, joka on noin 2-30 um, D[V,0,90]-hiukkaskoko, joka on noin 8-600 um, tai D[4,3]-hiukkaskoko, joka on noin 5-200 um.
4. Koostumus, joka käsittää jonkin patenttivaatimuksen 1-3 mukaista kiteistä muotoa, jolloin kiteisellä muodolla A on yksi tai useampi D[V,0,1]-hiukkaskoko, joka on noin 0,5—15 um, DI[V,0,50]-hiukkaskoko, joka on noin 2-30 um, D[V,0,90]- hiukkaskoko, joka on noin 8-600 um, tai D[4,3]-hiukkaskoko, joka on noin 5-200 um.
5. Lääkekoostumus, joka käsittää jonkin patenttivaatimuksen 1-3 mukaista kiteistä muotoa tai patenttivaatimuksen 4 mukaista koostumusta ja farmaseuttisesti hyväksyttävää kantoainetta.
6. Patenttivaatimuksen 5 mukainen lääkekoostumus, jolloin lääkekoostumus on tabletti tai jolloin lääkekoostumus käsittää (a) noin 25-400 mg (b) noin 50 mg (c) noin 100 mg tai (0) noin 150 mg (S)-2-(((S)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yylijamino)-N-(1-(2-metyyli-1- (neopentyyliamino)propan-2-yyli)-1 H-imidatsol-4-yyli)pentaaniamidin hydrobromidisuolaa.
7. Patenttivaatimuksen 5 tai 6 mukainen lääkekoostumus käytettäväksi kasvainten tai syövän hoidossa.
8. Patenttivaatimuksen 7 mukaisesti käytettävä lääkekoostumus, jolloin kasvaimet ovat desmoidikasvaimia tai jolloin syöpä on valittu ryhmästä, joka koostuu multippelista myeloomasta, syövästä, jossa on mutaatio Notch-reitin geenissä, adenoidikystisestä karsinoomasta ja akuutista lymfoblastisesta T-solkuleukemiasta.
9. Patenttivaatimuksen 7 tai 8 mukaisesti käytettävä lääkekoostumus, jossa (a) noin 50-500 mg
EP4010322 3 (b) noin 100-400 mg (c) noin 300 mg tai (d) noin 200 mg (S)-2-(((S)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yylijamino)-N-(1-(2-metyyli-1- (neopentyyliamino)propan-2-yyli)-1H-imidatsol-4-yyli)pentaaniamidin hydrobromidisuolaa annetaan päivittäin, jolloin valinnaisesti kokonaisvuorokausiannos annetaan kahtena erillisenä annoksena, jolloin edullisesti kokonaisvuorokausiannos annetaan kahtena erillisenä 150 mg:n tai 100 mg:n annoksena.
10. Patenttivaatimuksen 5 tai 6 mukainen lääkekoostumus käytettäväksi desmoidikasvaimen hoidossa.
11. Patenttivaatimuksen 10 mukaisesti käytettävä lääkekoostumus, jolloin (a) noin 100-400 mg tai (b) noin 300 mg (S)-2-(((S)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yylijamino)-N-(1-(2-metyyli-1- (neopentyyliamino)propan-2-yyli)-1 H-imidatsol-4-yyli)pentaaniamidin hydrobromidisuolaa annetaan päivittäin, jolloin kokonaisvuorokausiannos annetaan — valinnaisesti kahtena erillisenä annoksena.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/537,394 US10590087B1 (en) | 2019-08-09 | 2019-08-09 | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| PCT/US2019/045948 WO2021029854A1 (en) | 2019-08-09 | 2019-08-09 | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4010322T3 true FI4010322T3 (fi) | 2025-12-16 |
Family
ID=69778968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19758589.6T FI4010322T3 (fi) | 2019-08-09 | 2019-08-09 | (s)-2-(((s)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yyli)amino)-n-(1-(2-metyyli-1-(neopentyyliamino)propan-2-yyli)-1h-imidatsol-4-yyli)pentaaniamidin kiinteitä olomuotoja ja niiden käyttö |
Country Status (13)
| Country | Link |
|---|---|
| US (11) | US10590087B1 (fi) |
| JP (1) | JP2024149803A (fi) |
| KR (1) | KR20250030524A (fi) |
| ES (1) | ES3055762T3 (fi) |
| FI (1) | FI4010322T3 (fi) |
| FR (1) | FR26C1013I1 (fi) |
| LT (1) | LTPA2026516I1 (fi) |
| MA (1) | MA56748B1 (fi) |
| MX (1) | MX2025004371A (fi) |
| PL (1) | PL4010322T3 (fi) |
| SI (1) | SI4010322T1 (fi) |
| TW (2) | TWI919596B (fi) |
| ZA (1) | ZA202202325B (fi) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11884634B2 (en) * | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| ES3055762T3 (en) * | 2019-08-09 | 2026-02-16 | Pfizer | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
| US20230049311A1 (en) * | 2019-08-09 | 2023-02-16 | Springworks Therapeutics, Inc. | Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide |
| WO2021195362A1 (en) | 2020-03-26 | 2021-09-30 | Seagen Inc. | Methods of treating multiple myeloma |
| CN122537531A (zh) | 2020-08-20 | 2026-08-11 | 小利兰·斯坦福大学托管委员会 | 用于治疗以黏液分泌过多为特征的呼吸系统疾病的方法 |
| MX2024002590A (es) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Sintesis de nirogacestat. |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| MX2024005453A (es) * | 2021-11-05 | 2024-07-22 | Springworks Therapeutics Inc | Composiciones y tratamientos con nirogacestat. |
| AU2023215459A1 (en) * | 2022-02-01 | 2024-08-22 | Springworks Therapeutics, Inc. | Treatment of ovarian cancer with nirogacestat |
| WO2023174390A1 (zh) * | 2022-03-17 | 2023-09-21 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12667555B2 (en) | 2022-05-20 | 2026-06-30 | Springworks Therapeutics, Inc. | Treatment of ovarian cancer with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| JP2026508907A (ja) * | 2023-03-09 | 2026-03-13 | ▲蘇▼州科睿思制▲葯▼有限公司 | ニロガセスタット二臭化水素酸塩の結晶形、及びその調製方法並びに用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5160260A1 (es) | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| AP2379A (en) | 2004-03-23 | 2012-03-08 | Pfizer Prod Inc | Imidazole compounds for the treatment of neurodegenerative disorders. |
| US10211310B2 (en) | 2012-06-12 | 2019-02-19 | Novellus Systems, Inc. | Remote plasma based deposition of SiOC class of films |
| WO2015092614A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
| CA2990564A1 (en) * | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic amide derivative |
| US20190185559A1 (en) | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| WO2019053727A1 (en) | 2017-09-18 | 2019-03-21 | Ramot At Tel-Aviv University Ltd. | REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH |
| US20220133672A1 (en) * | 2018-12-18 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Notch inhibitors for the treatment of vascular malformations |
| US20230049311A1 (en) | 2019-08-09 | 2023-02-16 | Springworks Therapeutics, Inc. | Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide |
| ES3055762T3 (en) | 2019-08-09 | 2026-02-16 | Pfizer | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
-
2019
- 2019-08-09 ES ES19758589T patent/ES3055762T3/es active Active
- 2019-08-09 SI SI201931000T patent/SI4010322T1/sl unknown
- 2019-08-09 MA MA56748A patent/MA56748B1/fr unknown
- 2019-08-09 KR KR1020257005607A patent/KR20250030524A/ko active Pending
- 2019-08-09 FI FIEP19758589.6T patent/FI4010322T3/fi active
- 2019-08-09 US US16/537,394 patent/US10590087B1/en active Active
- 2019-08-09 PL PL19758589.6T patent/PL4010322T3/pl unknown
-
2020
- 2020-03-13 US US16/818,863 patent/US10710966B1/en active Active
- 2020-05-28 US US16/886,622 patent/US10941118B2/en active Active
- 2020-08-07 TW TW113145218A patent/TWI919596B/zh active
- 2020-08-07 TW TW109126829A patent/TWI867022B/zh active
-
2021
- 2021-02-19 US US17/180,296 patent/US11566006B2/en active Active
-
2022
- 2022-02-09 MX MX2025004371A patent/MX2025004371A/es unknown
- 2022-02-23 ZA ZA2022/02325A patent/ZA202202325B/en unknown
-
2023
- 2023-01-20 US US18/157,592 patent/US12297177B2/en active Active
- 2023-01-27 US US18/160,442 patent/US11820748B2/en active Active
- 2023-02-17 US US18/170,884 patent/US11845732B2/en active Active
- 2023-07-28 US US18/361,472 patent/US11905255B1/en active Active
- 2023-07-28 US US18/361,545 patent/US11884635B2/en active Active
-
2024
- 2024-01-16 US US18/414,019 patent/US12116347B2/en active Active
- 2024-08-16 JP JP2024136986A patent/JP2024149803A/ja active Pending
-
2025
- 2025-05-02 US US19/197,090 patent/US20260078096A1/en active Pending
-
2026
- 2026-03-17 FR FR26C1013C patent/FR26C1013I1/fr active Active
- 2026-04-23 LT LTPA2026516C patent/LTPA2026516I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292161B2 (en) | New methylquinazolinone derivatives | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| JP2023512175A5 (fi) | ||
| JP2023512174A5 (fi) | ||
| FI3429571T3 (fi) | Lsd1-inhibiittorien yhdistelmiä käytettäväksi kasvaintautien hoitamisessa | |
| ZA202202325B (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| HRP20130959T1 (hr) | Antikancerozni spojevi i farmaceutski pripravci koji ih sadrže | |
| EP4606427A3 (en) | Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof | |
| Wang et al. | Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2020512337A5 (fi) | ||
| JP2014516942A5 (fi) | ||
| AR119614A1 (es) | Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| US20210040050A1 (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| WO2021016256A3 (en) | Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors | |
| MY133527A (en) | Isoquinoline derivatives | |
| JP2016515550A5 (fi) | ||
| AU2019271151A1 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| WO2023129513A3 (en) | Bicyclic heteroaromatic inhibitors of nicotinamide n-methyltransferase, and compositions and uses thereof | |
| FI3506900T3 (fi) | Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension | |
| CA2535210A1 (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| JP4294957B2 (ja) | 金属錯体およびその治療的使用 | |
| EP3790553A1 (en) | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| US20110020217A1 (en) | Treatment of melanoma | |
| WO2009119980A3 (ko) | 미세소관 형성 저해제로서 유용한 벤조페논 티아졸 유도체 및 이의 제조 방법 |